Hyaluronic Acid Skin Randomized Trial: What the Evidence Says

Quick Answer

Hyaluronic Acid Skin Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Nonetheless, HA fillers are associated with certain limitations, including the necessity for supplementary chemical agents, a brief half-life, and restrictions on concentration. [Saffarian Zahra (2026); evidence level 2]
• Conversely, low molecular weight hyaluronic acids (-HAs), which result from the degradation of H-HAs, induce a cytokine response and stimulate angiogenesis. [Saffarian Zahra (2026); evidence level 2]
• Skin aging is a complex biological process driven by intrinsic senescence and extrinsic stimuli, with typical facial manifestations including reduced hydration, degradation of elastic and collagen fibers, rough epidermal texture, and fine line formation. [Cheng Haiyan (2026); evidence level 2]
• Despite NCHA's well-documented benefits, clinical practice urgently requires targeted, standardized protocols and large-sample data for the Chinese population to support evidence-based decision-making. [Cheng Haiyan (2026); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For hyaluronic acid skin randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Saffarian Zahra (2026). Combined Use of Botulinum Toxin A and Profhilo for Upper Face Rejuvenation: A Randomized Clinical Trial. DOI: 10.1002/hsr2.71973. PMCID: PMC13125427. PMID: 42063688. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open .... https://pmc.ncbi.nlm.nih.gov/articles/PMC13125427/
• Cheng Haiyan (2026). A Prospective, Multicenter, Randomized, Assessor-Blinded Study Assessing the Efficacy and Safety of Injectable Non-Cross-Linked Hyaluronic Acid for Improving Facial Skin Rejuvenation. DOI: 10.2147/CCID.S590699. PMCID: PMC13069964. PMID: 41971651. License: https://creativecommons.org/licenses/by-nc/4.0/ https://www.dovepress.com/terms.php http://creativecommons.org/licens.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13069964/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.